Cancer Genetics planning second follow-on

Cancer Genetics Inc. (NASDAQ:CGIX) proposed a follow-on underwritten by Aegis Capital, the second follow-on Cancer Genetics has proposed this year since raising $6.9 million in an April IPO. The diagnostic company raised $16.1 million in an August follow-on. Cancer Genetics markets its MatBA microarrays as aids in the diagnosis and prognosis of cancer. The tests, which are performed at the company's CLIA-certified laboratory, identify genomic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms. ...